Reported about 8 hours ago
Leerink analyst Joseph Schwartz has a positive outlook on BioMarin following its acquisition of Inozyme Pharma for $270 million, believing the deal could yield substantial revenue from the newly added INZ-701 therapy. The acquisition aligns with BioMarin's growth strategy and expertise in enzyme replacement therapies, suggesting that more business development deals may follow. Leerink maintains an Outperform rating on BioMarin's shares.
Source: YAHOO